- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Using an array of nanotube devices, each coated with a different organic material, researchers at the Israel Institute of Technology have developed diagnostic system that may be able to diagnose lung cancer simply by sampling a patient's breath. The results of this study, which was led by Hossam Haick, Ph.D., appear in the journal Nano Letters.
Dr. Haick and his collaborators first created individual devices consisting of random networks of single-walled carbon nanotubes coated with 1 of 10 different insulating nonpolymeric organic materials. The investigators used standard microprocessor fabrication techniques to create the sensors. Thanks to the different organic materials used to coat the nanotubes, each sensing device provided a unique response when exposed to wide variety of the more than 200 volatile organic chemicals present in human breath.
To calibrate the devices, the investigators captured the breath of 15 nonsmoking healthy patients and 15 individuals with stage 4 lung cancer. Next, they concentrated the organic compounds in each breath sample using a method known as solid phase microextraction and then analyzed each sample using gas chromatography-mass spectrometry (GC-MS). GC-MS is a highly accurate technique that is too expensive and time consuming to find use as a routine diagnostic assay. The researchers then ran the same samples through their sensor array; the electrical output of the test devices changed in a way that was characteristic of the exact mixture of organic compounds found in the breath samples.
From these data, the investigators were able to distinguish between two response patterns from each of the 10 array members. There was no overlap in the response patterns between the healthy and lung cancer patients in these first tests. The researchers are now testing their system on a much larger group of patients and healthy subjects.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016